As per NPPA Order S.O. 5690(E) dated 17 October 2026, the trade margin on 137 non-scheduled anti-cancer medicines is capped at 30%. Hetero’s revised MRPs take effect on 9 November 2026.
Patients and partners with questions about the revised prices are welcome to speak to their doctor, pharmacist or hospital.
Source: NPPA Order S.O. 5690(E), The Gazette of India, 17 October 2026.
The HHCL Division of Hetero Healthcare is focused on providing therapeutic solutions across anti-infective care and the management of bacterial, fungal, and other infection-related conditions. The division aims to support healthcare professionals with dependable treatment options for infections encountered across different clinical settings, helping address both routine and more complex patient-care requirements.
Its therapeutic portfolio encompasses key areas such as antibacterial and antifungal therapy, respiratory tract infections, urinary tract infections, gastrointestinal infections, and other infectious conditions. Through a range of established anti-infective therapies and supportive treatment options, HHCL strives to enable effective clinical management while addressing the diverse needs of patients with infection-related illnesses.
Backed by Hetero Healthcare’s commitment to quality, accessibility, innovation, and patient-centric care, the HHCL Division continues to contribute to the evolving landscape of infection management. With its focused anti-infective portfolio, the division aims to support healthcare professionals in delivering appropriate treatment and contribute to improved patient care and clinical outcomes.
View by-
